featured
Efficacy of Abemaciclib Plus Endocrine Therapy in Patients With HR+/HER2−, Node-Positive, High-Risk Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Lancet Oncol 2022 Dec 05;[EPub Ahead of Print], SRD Johnston, M Toi, J O'Shaughnessy, P Rastogi, M Campone, P Neven, CS Huang, J Huober, GG Jaliffe, I Cicin, SM Tolaney, MP Goetz, HS Rugo, E Senkus, L Testa, L Del Mastro, C Shimizu, R Wei, A Shahir, M Munoz, B San Antonio, V André, N Harbeck, M MartinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.